Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment
Authors:
- 1 October 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 81 (10) , 993
Abstract
Importance: Subjective cognitive decline (SCD) is recognized to be in the Alzheimer disease (AD) cognitive continuum. The SCD Initiative International Working Group recently proposed SCD-plus (SCD+) features that increase risk for future objective cognitive decline but that have not been assessed in a large community-based setting.Objective: To assess SCD risk for mild cognitive impairment (MCI), AD, and all-cause dementia, using SCD+ criteria among cognitively normal adults.Design, Setting, and Participants: The Framingham Heart Study, a community-based prospective cohort study, assessed SCD between 2005 and 2019, with up to 12 years of follow-up. Participants 60 years and older with normal cognition at analytic baseline were included. Cox proportional hazards (CPH) models were adjusted for baseline age, sex, education, APOE ε4 status, and tertiles of AD polygenic risk score (PRS), excluding the APOE region. Data were analyzed from May 2021 to November 2023.Exposure: SCD was assessed longitudinally using a single question and considered present if endorsed at the last cognitively normal visit. It was treated as a time-varying variable, beginning at the first of consecutive, cognitively normal visits, including the last, at which it was endorsed.Main Outcomes and Measures: Consensus-diagnosed MCI, AD, and all-cause dementia.Results: This study included 3585 participants (mean [SD] baseline age, 68.0 [7.7] years; 1975 female [55.1%]). A total of 1596 participants (44.5%) had SCD, and 770 (21.5%) were carriers of APOE ε4. APOE ε4 and tertiles of AD PRS status did not significantly differ between the SCD and non-SCD groups. MCI, AD, and all-cause dementia were diagnosed in 236 participants (6.6%), 73 participants (2.0%), and 89 participants (2.5%), respectively, during follow-up. On average, SCD preceded MCI by 4.4 years, AD by 6.8 years, and all-cause dementia by 6.9 years. SCD was significantly associated with survival time to MCI (hazard ratio [HR], 1.57; 95% CI, 1.22-2.03; P <.001), AD (HR, 2.98; 95% CI, 1.89-4.70; P <.001), and all-cause dementia (HR, 2.14; 95% CI, 1.44-3.18; P <.001). After adjustment for APOE and AD PRS, the hazards of SCD were largely unchanged.Conclusions and Relevance: Results of this cohort study suggest that in a community setting, SCD reflecting SCD+ features was associated with an increased risk of future MCI, AD, and all-cause dementia with similar hazards estimated in clinic-based settings. SCD may be an independent risk factor for AD and other dementias beyond the risk incurred by APOE ε4 and AD PRS.Keywords
This publication has 59 references indexed in Scilit:
- Subjective Cognitive Decline: Level of Risk for Future Dementia and Mild Cognitive Impairment, a Meta-Analysis of Longitudinal StudiesNeuropsychology Review, 2021
- NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of StagesAnnals of Neurology, 2021
- Prediction of Dementia by Subjective Memory ImpairmentEffects of Severity and Temporal Association With Cognitive ImpairmentDementia and Subjective Memory ImpairmentArchives of General Psychiatry, 2010
- Progression of Mild Cognitive Impairment to Dementia in Clinic- vs Community-Based CohortsArchives of Neurology, 2009
- Clinical characteristics of individuals with subjective memory loss in Western Australia: results from a cross-sectional surveyInternational Journal of Geriatric Psychiatry, 2001
- Are memory complaints predictive for dementia? A review of clinical and population-based studiesInternational Journal of Geriatric Psychiatry, 2000
- Do memory complaints indicate the presence of cognitive impairment? - Results of a field studyEuropean Archives of Psychiatry and Clinical Neuroscience, 1999
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997
- Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studiesAnnals of Neurology, 1994